These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25301170)

  • 1. Mechanistic understanding for the greater sensitivity of monkeys to antisense oligonucleotide-mediated complement activation compared with humans.
    Shen L; Frazer-Abel A; Reynolds PR; Giclas PC; Chappell A; Pangburn MK; Younis H; Henry SP
    J Pharmacol Exp Ther; 2014 Dec; 351(3):709-17. PubMed ID: 25301170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Repeated Complement Activation Associated with Chronic Treatment of Cynomolgus Monkeys with 2'-O-Methoxyethyl Modified Antisense Oligonucleotide.
    Shen L; Engelhardt JA; Hung G; Yee J; Kikkawa R; Matson J; Tayefeh B; Machemer T; Giclas PC; Henry SP
    Nucleic Acid Ther; 2016 Aug; 26(4):236-49. PubMed ID: 27140858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum.
    Henry SP; Jagels MA; Hugli TE; Manalili S; Geary RS; Giclas PC; Levin AA
    Nucleic Acid Ther; 2014 Oct; 24(5):326-35. PubMed ID: 25093529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement C3d/C4d Deposition on Platelets Correlates with 2'-O-Methoxyethyl Antisense Oligonucleotide-Induced Thrombocytopenia in Monkeys.
    Shen L; Wong A; Oneda S; Curtis BR; Schroeder J; Zanardi T; Engelhardt JA; Henry SP; Narayanan P
    Nucleic Acid Ther; 2023 Jun; 33(3):209-225. PubMed ID: 37093125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action.
    Henry SP; Giclas PC; Leeds J; Pangburn M; Auletta C; Levin AA; Kornbrust DJ
    J Pharmacol Exp Ther; 1997 May; 281(2):810-6. PubMed ID: 9152389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry
    Zanardi TA; Korbmacher B; Boone L; Engelhardt JA; Wang Y; Burel S; Prill B; Aghajan M; Guo S; Henry SP
    J Pharmacol Exp Ther; 2021 Apr; 377(1):51-63. PubMed ID: 33431610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies.
    Kim TW; Kim KS; Seo JW; Park SY; Henry SP
    J Pharmacol Toxicol Methods; 2014; 69(1):49-60. PubMed ID: 24211663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2'-MOE-Modified Antisense Oligonucleotide.
    Narayanan P; Shen L; Curtis BR; Bourdon MA; Nolan JP; Gupta S; Hoffmaster C; Zhou F; Christian B; Schaubhut JL; Greenlee S; Burel SA; Witztum JL; Engelhardt JA; Henry SP
    Toxicol Sci; 2018 Aug; 164(2):613-626. PubMed ID: 29846725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2.
    Zanardi TA; Han SC; Jeong EJ; Rime S; Yu RZ; Chakravarty K; Henry SP
    J Pharmacol Exp Ther; 2012 Nov; 343(2):489-96. PubMed ID: 22915769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.
    Yu RZ; Lemonidis KM; Graham MJ; Matson JE; Crooke RM; Tribble DL; Wedel MK; Levin AA; Geary RS
    Biochem Pharmacol; 2009 Mar; 77(5):910-9. PubMed ID: 19056355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats.
    Butler M; Hayes CS; Chappell A; Murray SF; Yaksh TL; Hua XY
    Neuroscience; 2005; 131(3):705-15. PubMed ID: 15730875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys.
    Burel SA; Han SR; Lee HS; Norris DA; Lee BS; Machemer T; Park SY; Zhou T; He G; Kim Y; MacLeod AR; Monia BP; Lio S; Kim TW; Henry SP
    Nucleic Acid Ther; 2013 Jun; 23(3):213-27. PubMed ID: 23692080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism and Disposition of Volanesorsen, a 2'-
    Post N; Yu R; Greenlee S; Gaus H; Hurh E; Matson J; Wang Y
    Drug Metab Dispos; 2019 Oct; 47(10):1164-1173. PubMed ID: 31350288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotide.
    Grossman TR; Carrer M; Shen L; Johnson RB; Hettrick LA; Henry SP; Monia BP; McCaleb ML
    Mol Vis; 2017; 23():561-571. PubMed ID: 28855795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
    Geary RS; Yu RZ; Watanabe T; Henry SP; Hardee GE; Chappell A; Matson J; Sasmor H; Cummins L; Levin AA
    Drug Metab Dispos; 2003 Nov; 31(11):1419-28. PubMed ID: 14570775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique O-methoxyethyl ribose-DNA chimeric oligonucleotide induces an atypical melanoma differentiation-associated gene 5-dependent induction of type I interferon response.
    Burel SA; Machemer T; Ragone FL; Kato H; Cauntay P; Greenlee S; Salim A; Gaarde WA; Hung G; Peralta R; Freier SM; Henry SP
    J Pharmacol Exp Ther; 2012 Jul; 342(1):150-62. PubMed ID: 22505629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides.
    Ackermann EJ; Guo S; Benson MD; Booten S; Freier S; Hughes SG; Kim TW; Jesse Kwoh T; Matson J; Norris D; Yu R; Watt A; Monia BP
    Amyloid; 2016 Sep; 23(3):148-157. PubMed ID: 27355239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys.
    Webb MS; Tortora N; Cremese M; Kozlowska H; Blaquiere M; Devine DV; Kornbrust DJ
    Antisense Nucleic Acid Drug Dev; 2001 Jun; 11(3):155-63. PubMed ID: 11446591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN.
    Geary RS; Wancewicz E; Matson J; Pearce M; Siwkowski A; Swayze E; Bennett F
    Biochem Pharmacol; 2009 Aug; 78(3):284-91. PubMed ID: 19393225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
    Zellweger T; Miyake H; Cooper S; Chi K; Conklin BS; Monia BP; Gleave ME
    J Pharmacol Exp Ther; 2001 Sep; 298(3):934-40. PubMed ID: 11504787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.